Spots Global Cancer Trial Database for Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
Official Title: Phase II Clinical Trial of Dasatinib First Line Therapy for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Study ID: NCT01464411
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate effectiveness of Dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in Japan.
Detailed Description:
Eligibility
Minimum Age: 20 Months
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Kanto CML Study Group, Tokyo, , Japan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
